Want to see CTOR full AI Analyst Report?
Top Page
Citius Oncology
(NASDAQ:CTOR)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.65
▲(16.61% Upside)
Action:Reiterated
Date:08/05/26
CTOR scores low-to-mid primarily due to weak financial performance (pre-revenue, widening losses, and increasing cash burn), which outweighs positives. Corporate events provide a meaningful offset via reported LYMPHIR commercial traction, encouraging early clinical expansion data, and added liquidity. Technicals and valuation are neutral-to-negative, with the stock still below key longer-term moving averages and a loss-driven negative P/E.
Positive Factors
Commercial traction for LYMPHIR
Sustained institutional uptake and formulary additions create a durable commercial foundation: widespread availability across academic, NCCN and community centers supports recurring wholesale orders and predictable revenue recognition as institutions place patient orders, reducing early-launch execution risk over the next 2–6 months.
Negative Factors
Pre-revenue status with widening operating losses
CTOR remains pre-revenue while operating losses have grown materially, a structural headwind. Continued negative earnings mean the company must rely on external funding to sustain commercialization and R&D, increasing execution and dilution risk if revenue ramps slower than planned over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial traction for LYMPHIR
Sustained institutional uptake and formulary additions create a durable commercial foundation: widespread availability across academic, NCCN and community centers supports recurring wholesale orders and predictable revenue recognition as institutions place patient orders, reducing early-launch execution risk over the next 2–6 months.
Read all positive factors
Citius Oncology (CTOR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$55.07M
Dividend YieldN/A
Average Volume (3M)56.61K
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees285
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-0.47
Shares Outstanding92,981,200
10 Day Avg. Volume44,100
30 Day Avg. Volume56,609
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-27.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside614.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.52
Revenue Forecast (FY)$20.82M
Citius Oncology Business Overview & Revenue Model
Company Description
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling...
How the Company Makes Money
null...
Citius Oncology Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.61M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 4.49M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -41.08M | -23.49M | -20.57M | -12.12M | 0.00 |
| Net Income | -42.51M | -24.76M | -21.15M | -12.70M | -10.87M |
Balance Sheet | |||||
| Total Assets | 100.70M | 100.94M | 84.37M | 47.73M | 42.69M |
| Cash, Cash Equivalents and Short-Term Investments | 2.63M | 3.92M | 112.00 | 0.00 | 0.00 |
| Total Debt | 3.80M | 3.80M | 3.80M | 0.00 | 0.00 |
| Total Liabilities | 65.43M | 56.08M | 38.23M | 22.20M | 6.42M |
| Stockholders Equity | 35.27M | 44.87M | 46.14M | 25.54M | 36.27M |
Cash Flow | |||||
| Free Cash Flow | -16.86M | -5.49M | 126.35K | -601.30K | -47.97K |
| Operating Cash Flow | -16.86M | -5.49M | 126.35K | -601.30K | -47.97K |
| Investing Cash Flow | -10.86M | -5.75M | -5.00M | -1.32M | -67.32M |
| Financing Cash Flow | 30.36M | 15.17M | 4.87M | 1.66M | 67.66M |
Citius Oncology Risk Analysis
Citius Oncology disclosed 52 risk factors in its most recent earnings report. Citius Oncology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Citius Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $29.99B | 35.73 | 4.52% | ― | 0.53% | -45.79% | |
63 Neutral | $6.84B | 14.87 | 8.43% | 3.72% | 6.84% | 61.67% | |
58 Neutral | $3.56B | 16.94 | 23.44% | 0.59% | -2.45% | -70.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $55.07M | -1.26 | -99.47% | ― | ― | ― | |
43 Neutral | $26.93M | -0.01 | 875.03% | 2.78% | ― | ― |
* Healthcare Sector Average
CTOR
Citius Oncology
0.79
-1.13
-58.90%
BIIB
Biogen
206.63
77.29
59.76%
GRFS
Grifols SA
7.93
-2.30
-22.46%
SRXH
SRx Health Solutions
1.39
-21.14
-93.83%
SCLX
Scilex Holding Company
6.52
-2.76
-29.76%
OGN
Organon
13.57
4.93
57.01%
Citius Oncology Corporate Events
Business Operations and StrategyFinancial Disclosures
Citius Oncology reports strong LYMPHIR commercial momentum
Positive
Aug 5, 2026
On August 5, 2026, Citius Oncology reported strong commercial momentum for its CTCL therapy LYMPHIR, highlighting rapid growth in institutional uptake during the quarter ended June 30, 2026. New institutional accounts ordering LYMPHIR rose 78% qua...
Business Operations and StrategyProduct-Related Announcements
Citius Oncology Highlights Promising LYMPHIR Combo Phase 1 Data
Positive
Jun 1, 2026
On June 1, 2026, Citius Oncology reported Phase 1 data from an investigator-initiated study of its CTCL drug LYMPHIR in combination with pembrolizumab in heavily pre-treated patients with recurrent or refractory gynecologic malignancies. Presented...
Business Operations and StrategyPrivate Placements and Financing
Citius Oncology Secures New Financing to Support LYMPHIR
Positive
May 6, 2026
On May 5, 2026, Citius Oncology secured up to $36.5 million in combined debt and equity-related capital to support the commercialization of LYMPHIR, its recently launched cutaneous T‑cell lymphoma therapy. The financings are aimed at funding...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.